NMRA · Neumora Therapeutics, Inc.
$1.60
-0.13 (-7.51%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$300.63M
Shares
187.90M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-06-30 | 6,255 | $1.72 | $10,759 |
| 2026-06-29 | 305,905 | $1.64 | $501,684 |
| 2026-06-26 | 183 | $1.51 | $276 |
| 2026-06-25 | 183 | $1.46 | $267 |
| 2026-06-22 | 3,161 | $1.51 | $4,773 |
| 2026-06-18 | 3,161 | $1.53 | $4,836 |
| 2026-06-17 | 17,998 | $1.56 | $28,077 |
Showing 1–7 of 7 settlements
Key facts
CIK
1885522
CUSIP
640979100
13F (30d)
114 filings
112 filers
Visit website
Investor relations